NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.18 -2.75 (-3.36%) GOLD FUTURES
2,328.10 +25.20 (+1.09%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,753.97 -1,969.18 (-4.13%)
CRISPR Therapeutics AG (CRSP)
After hours:
| Previous close | 52.99 |
| Open | 53.16 |
| Bid | 53.74 x 500 |
| Ask | 53.82 x 500 |
| Day's range | 52.74 - 55.97 |
| 52-week range | 37.55 - 91.10 |
| Volume | |
| Avg. volume | 1,724,404 |
| Market cap | 4.568B |
| Beta (5Y monthly) | 1.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
- Zacks
CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.91, moving +0.34% from the previous trading session.
- Reuters
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday. Mammoth's CRISPR-based gene editing platform and Regeneron's delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver. CRISPR, discovered by Jennifer Doudna and CRISPR Therapeutics co-founder Emmanuelle Charpentier, uses molecular "scissors" to trim faulty parts of genes that can then be disabled or replaced with new strands of normal DNA.
